Healthcare Industry News: Magnetic Resonance Imaging
News Release - October 24, 2019
European Symposium to Advance Adoption of MRI-Guided Radiation TherapyEducational Event to Feature Presentations from MRIdianŽ Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy
CLEVELAND, Oct. 24, 2019 -- (Healthcare Sales & Marketing Network) -- Clinicians interested in learning more about MRI-guided radiation therapy can attend a day-long symposium on Friday, November 14, 2019 in Rome to understand the strategic, economic, clinical and technical aspects of starting an MR-image guided radiation therapy program. The Symposium will feature presentations from various experts in MRI-guided radiation therapy and an update on the Health Economics in Radiation Oncology Project (HERO), titled "Access to Innovative Radiotherapy: How to Make it Happen from an Economic Perspective," given by co-chair and past president of the European Society for Radiotherapy and Oncology (ESTRO), Professor Yolande Lievens.
MRI-guided radiation therapy combines Magnetic Resonance Imaging (MRI) with radiation delivery to bring soft-tissue visibility to the treatment of cancer. ViewRay's MRIdian became the world's first MRI-guided radiation therapy system with patient treatments commencing in 2014. With five years of clinical usage, MRIdian represents a new paradigm in radiation oncology allowing clinicians to visualize, adapt, and target using diagnostic-quality anatomical detail that's simply unavailable with conventional IGRT technologies.
The Symposium, titled "Five Years & Counting: Clinical Experience on MRIdian," will cover current and future applications for MRI-guided radiation therapy including on-table adaptive therapy and stereotactic body radiation therapy (SBRT). Presentations will also cover physics considerations, functional imaging, ongoing studies and recent clinical findings. The event will conclude with a tour of the MRIdian MRI-guided Radiation Therapy System at Gemelli ART.
"We look forward to welcoming clinicians from around the world to Rome to learn more about the ground-breaking role of MRI-guided radiation therapy in improving cancer care," said Professor Vincenzo Valentini, M.D., Professor of Radiation Oncology and Chair of the Radiology, Radiation Oncology and Hematology Department at the Gemelli ART, Fondazione Policlinico Universitario A.Gemelli IRCCS in Rome. "We're bringing together some of the field's foremost experts to discuss all facets of MRI-guided radiation therapy from the economics and implementation to quality assurance and clinical use. In a single day, attendees will gather all the information, answers and best practices they'd need in order to successfully launch an MRI-guided radiation therapy program."
Presentations featured in the Symposium agenda include:
- Welcome Remarks Vincenzo Valentini, M.D., Gemelli ART, Rome, Italy
- MR-Guided RT Primer (The MRIdian Advantage) Martin Fuss, M.D., Chief Medical Officer, ViewRay
- Considerations and Challenges of MR-Guided RT (Physics) Kristian Boye Ph.D., Rigshospitalet, Copenhagen, Denmark
- On-Table Adaptive MR Image-Guided RT: Considerations for QA Lorenzo Placidi, medical physicist, Gemelli ART, Rome, Italy
- MR-Guided Renal Cell Cancer SBRT Anna Bruynzeel, M.D., Ph.D., Amsterdam UMC, Netherlands
- Clinical Studies/Clinical Research Overview Paul Strong, Ph.D., Senior Director, Medical Affairs, ViewRay
- Access to Innovative Radiotherapy: How to Make it Happen from an Economic Perspective Yolande Lievens, M.D., Ph.D., Ghent University Hospital, Ghent, Belgium, ESTRO-HERO
- On-Table Adaptive MR-Guided SBRT: Clinical Experience at Gemelli Luca Boldrini, M.D., Gemelli ART, Rome, Italy
- Decision Making Process Towards MRIdian Pascal Fenoglietto, M.D., Institut du Cancer Montpellier (ICM)
- MR-Guided SBRT, Results Phase 2: Prostate SMART study (Amsterdam UMC Experience) Frank Lagerwaard, M.D., Amsterdam UMC, Netherlands
- Closing Remarks Piercarlo Gentile, M.D., San Pietro Fatebenefratelli UPMC, Rome, Italy
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdianŽ radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2019 and ViewRay's conference call to discuss its second quarter results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2019 and June 30, 2019, as updated periodically by the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.